Sulzer Medica float will go ahead says CEO (Chief Executive Officer):
This article was originally published in Clinica
The CEO of Sulzer, the parent company that owns 74% of Sulzer Medica, said last week that the ongoing recall and programme of revision surgery presently affecting Sulzer Medica will not delay the scheduled flotation on July 10. Fred Kindle also told Finanz und Wirtschaft that the lawyers had ruled out the parent company assisting Sulzer Medica if the damages reach the estimated $1 billion.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.